Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials

Besmir Nreu; Ilaria Dicembrini; Federico Tinti; Edoardo Mannucci; Matteo Monami

doi:10.1016/j.diabres.2020.108087

Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials

Diabetes Res Clin Pract. 2020 Mar:161:108087. doi: 10.1016/j.diabres.2020.108087. Epub 2020 Feb 19.

Authors

Besmir Nreu¹, Ilaria Dicembrini¹, Federico Tinti¹, Edoardo Mannucci¹, Matteo Monami²

Affiliations

¹ Diabetology, Careggi Hospital and University of Florence, Italy.
² Diabetology, Careggi Hospital and University of Florence, Italy. Electronic address: matteo.monami@unifi.it.

PMID: 32084455
DOI: 10.1016/j.diabres.2020.108087

Abstract

Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) has been associated with cholelithiasis in a previous meta-analysis. The publication of new trials suggests the need for an update. We collected trials with GLP1-RA vs. other therapies, calculating Mantel-Haenszel odds ratio (MH-OR, 95%CI). GLP1-RA significantly increased the risk of cholelithiasis (MH-OR 1.28 [1.11, 1.48]).

Keywords: Glucagon-Like Peptide-1 Receptor Agonists; Meta-analysis.

Publication types

Meta-Analysis

MeSH terms

Cholelithiasis / chemically induced*
Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / drug therapy
Glucagon-Like Peptide-1 Receptor Agonists*
Humans
Hypoglycemic Agents / adverse effects*
Randomized Controlled Trials as Topic

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists